Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Non-Current Assets (2016 - 2025)

Corcept Therapeutics' Other Non-Current Assets history spans 10 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 22.04% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, down 22.04%, while the annual FY2025 figure was $5.2 million, 22.04% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $5.2 million at Corcept Therapeutics, down from $8.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $8.3 million in Q2 2025 and bottomed at $1.8 million in Q2 2022.
  • The 5-year median for Other Non-Current Assets is $5.1 million (2022), against an average of $5.4 million.
  • The largest annual shift saw Other Non-Current Assets crashed 55.7% in 2022 before it soared 140.62% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.1 million in 2021, then skyrocketed by 64.06% to $5.1 million in 2022, then rose by 29.32% to $6.5 million in 2023, then grew by 1.05% to $6.6 million in 2024, then fell by 22.04% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Other Non-Current Assets are $5.2 million (Q4 2025), $8.0 million (Q3 2025), and $8.3 million (Q2 2025).